SRR934773
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 118.42969776609723
- age_years
- 51
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.425
- UV_RESPONSE_DN+0.380
- HEDGEHOG_SIGNALING+0.370
- CHOLESTEROL_HOMEOSTASIS+0.255
- APICAL_JUNCTION+0.254
- APICAL_SURFACE+0.241
- TGF_BETA_SIGNALING+0.230
- INFLAMMATORY_RESPONSE+0.227
- KRAS_SIGNALING_UP+0.217
- ESTROGEN_RESPONSE_EARLY+0.212
Top 10 suppressed
- MYC_TARGETS_V1-0.415
- DNA_REPAIR-0.329
- MYC_TARGETS_V2-0.328
- OXIDATIVE_PHOSPHORYLATION-0.282
- UNFOLDED_PROTEIN_RESPONSE-0.207
- ALLOGRAFT_REJECTION-0.159
- ANGIOGENESIS-0.141
- TNFA_SIGNALING_VIA_NFKB-0.088
- XENOBIOTIC_METABOLISM-0.075
- FATTY_ACID_METABOLISM-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598057 | fetal | fetal | 0.722 |
| 2 | TCGA-05-4424-01A-22R-1858-07 | — | cohortA1 | 0.722 |
| 3 | SRR934759 | — | — | 0.718 |
| 4 | SRR934850 | — | — | 0.710 |
| 5 | SRR17866851 | — | — | 0.701 |
| 6 | TCGA-AO-A0JA-01A-11R-A056-07 | — | A | 0.701 |
| 7 | TCGA-AQ-A1H3-01A-31R-A13Q-07 | — | A | 0.694 |
| 8 | TCGA-GC-A3OO-01A-11R-A22U-07 | — | — | 0.692 |
| 9 | SRR1098336 | GTEX | — | 0.683 |
| 10 | SRR934720 | — | — | 0.682 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.425 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.255 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.254 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.241 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.227 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.217 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.212 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.198 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.185 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.179 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.178 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.171 | Inavolisib | — uncovered |
| COMPLEMENT | 0.165 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| APOPTOSIS | 0.149 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.149 | Inavolisib | — uncovered |